115 related articles for article (PubMed ID: 2839727)
1. Protection from progressive renal failure and hyperparathyroid bone remodeling by WR-2721.
Hirschel-Scholz S; Charhon S; Rizzoli R; Caverzasio J; Paunier L; Bonjour JP
Kidney Int; 1988 May; 33(5):934-41. PubMed ID: 2839727
[TBL] [Abstract][Full Text] [Related]
2. Prevention of parathyroid hormone-dependent nephrocalcinosis by chronic administration of the organic phosphorothioate WR-2721.
Hirschel-Scholz S; Caverzasio J; Bonjour JP
Calcif Tissue Int; 1987 Feb; 40(2):103-8. PubMed ID: 3032378
[TBL] [Abstract][Full Text] [Related]
3. Bone and parathyroid inhibitory effects of S-2(3-aminopropylamino)ethylphosphorothioic acid. Studies in experimental animals and cultured bone cells.
Attie MF; Fallon MD; Spar B; Wolf JS; Slatopolsky E; Goldfarb S
J Clin Invest; 1985 Apr; 75(4):1191-7. PubMed ID: 2985652
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of parathyroid hormone secretion and parathyroid hormone-independent diminution of tubular calcium reabsorption by WR-2721, a unique hypocalcemic agent.
Hirschel-Scholz S; Caverzasio J; Bonjour JP
J Clin Invest; 1985 Nov; 76(5):1851-6. PubMed ID: 2997292
[TBL] [Abstract][Full Text] [Related]
5. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
6. Interference of WR-2721 with magnesium metabolism: mechanism of action.
Hirschel-Scholz S; Paunier L; Bonjour JP
Miner Electrolyte Metab; 1988; 14(2-3):114-20. PubMed ID: 2837628
[TBL] [Abstract][Full Text] [Related]
7. Prevention of enhanced parathyroid hormone secretion, synthesis and hyperplasia by mild dietary phosphorus restriction in early chronic renal failure in rats: possible direct role of phosphorus.
Yi H; Fukagawa M; Yamato H; Kumagai M; Watanabe T; Kurokawa K
Nephron; 1995; 70(2):242-8. PubMed ID: 7566311
[TBL] [Abstract][Full Text] [Related]
8. Normalization of hypercalcemia associated with a decrease in renal calcium reabsorption in Leydig cell tumor-bearing rats treated with WR-2721.
Hirschel-Scholz S; Caverzasio J; Rizzoli R; Bonjour JP
J Clin Invest; 1986 Jul; 78(1):319-22. PubMed ID: 3013941
[TBL] [Abstract][Full Text] [Related]
9. Parathyroid removal prevents the progression of chronic renal failure induced by high protein diet.
Shigematsu T; Caverzasio J; Bonjour JP
Kidney Int; 1993 Jul; 44(1):173-81. PubMed ID: 8355459
[TBL] [Abstract][Full Text] [Related]
10. Hypocalcaemic effect of WR-2721, S-2 (3-aminopropylamino) ethyl-phosphorothioic acid in an anuric haemodialysis patient.
Zingraff J; Bourdeau A; Clair F; Kindermans C; Buisson C; Manganella G; Sachs C; Drüeke T
Nephrol Dial Transplant; 1987; 2(1):48-52. PubMed ID: 3037448
[TBL] [Abstract][Full Text] [Related]
11. 22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.
Monier-Faugere MC; Geng Z; Friedler RM; Qi Q; Kubodera N; Slatopolsky E; Malluche HH
Kidney Int; 1999 Mar; 55(3):821-32. PubMed ID: 10027919
[TBL] [Abstract][Full Text] [Related]
12. Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism.
Li X; Yu L; Asuncion F; Grisanti M; Alexander S; Hensley K; Han CY; Niu QT; Dwyer D; Villasenor K; Stolina M; Dean C; Ominsky MS; Ke HZ; Tomlinson JE; Richards WG
Bone; 2017 Dec; 105():163-172. PubMed ID: 28867373
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of the hypocalcemic agent WR-2721 and its acute and chronic application in eu- and hyperparathyroidism.
Hirschel-Scholz S; Caverzasio J; Bonjour JP
Adv Exp Med Biol; 1986; 208():367-70. PubMed ID: 3031946
[No Abstract] [Full Text] [Related]
14. In vivo and in vitro effects of WR-2721 in experimental hypercalcemia in the rat.
Weiss J; Walker ST; Fallon M; Goldfarb S
J Pharmacol Exp Ther; 1986 Sep; 238(3):969-73. PubMed ID: 3018229
[TBL] [Abstract][Full Text] [Related]
15. Reduction of tetrachloro(dl-trans)1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) toxicity by the administration of diethyldithiocarbamate (DDTC), S-2(3-aminopropylamino)ethylphosphorothioic acid (WR-2721), or sodium selenite in the Fischer 344 rat.
Carfagna PF; Chaney SG; Chang J; Holbrook DJ
Fundam Appl Toxicol; 1990 May; 14(4):706-19. PubMed ID: 2163338
[TBL] [Abstract][Full Text] [Related]
16. Short-term administration of the bisphosphonate ibandronate increases bone volume and prevents hyperparathyroid bone changes in mild experimental renal failure.
Geng Z; Monier-Faugere MC; Bauss F; Malluche HH
Clin Nephrol; 2000 Jul; 54(1):45-53. PubMed ID: 10939756
[TBL] [Abstract][Full Text] [Related]
17. Effect of verapamil on bone resorption and formation in uremic rats.
Chagnac A; Gazit D; Zahavi I; Sela J; Levi J
Miner Electrolyte Metab; 1989; 15(5):291-4. PubMed ID: 2811787
[TBL] [Abstract][Full Text] [Related]
18. WR-2721 reduces bone loss after hindlimb tenotomy in rats.
Shaker JL; Fallon MD; Goldfarb S; Farber J; Attie MF
J Bone Miner Res; 1989 Dec; 4(6):885-90. PubMed ID: 2558504
[TBL] [Abstract][Full Text] [Related]
19. Effects of parathyroid hormone on renal tubular proteinases.
Schaefer L; Malchow M; Schaefer RM; Ling H; Heidland A; Massry SG
Miner Electrolyte Metab; 1996; 22(1-3):182-6. PubMed ID: 8676815
[TBL] [Abstract][Full Text] [Related]
20. Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency.
Mizobuchi M; Hatamura I; Ogata H; Saji F; Uda S; Shiizaki K; Sakaguchi T; Negi S; Kinugasa E; Koshikawa S; Akizawa T
J Am Soc Nephrol; 2004 Oct; 15(10):2579-87. PubMed ID: 15466262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
